IQVIA Holdings Inc. (NYSE:IQV) Given Consensus Rating of “Moderate Buy” by Brokerages

IQVIA Holdings Inc. (NYSE:IQV) has been assigned an average rating of “Moderate Buy” from the seventeen ratings firms that are currently covering the stock, MarketBeat reports. Three analysts have rated the stock with a hold rating and fourteen have given a buy rating to the company. The average twelve-month price target among analysts that have issued a report on the stock in the last year is $224.8235.

A number of brokerages recently commented on IQV. Robert W. Baird increased their price target on IQVIA from $230.00 to $249.00 and gave the company an “outperform” rating in a research note on Wednesday, July 1st. HSBC reaffirmed a “buy” rating and set a $240.00 price target on shares of IQVIA in a research note on Monday, July 6th. Weiss Ratings downgraded shares of IQVIA from a “hold (c)” rating to a “hold (c-)” rating in a report on Monday, May 4th. Morgan Stanley restated an “equal weight” rating and issued a $200.00 price target (down from $225.00) on shares of IQVIA in a research report on Wednesday, June 17th. Finally, Evercore restated an “outperform” rating and set a $185.00 target price on shares of IQVIA in a research report on Wednesday, April 8th.

IQVIA Price Performance

NYSE IQV traded down $0.84 on Friday, reaching $208.13. The company had a trading volume of 747,394 shares, compared to its average volume of 1,464,238. The company has a quick ratio of 0.75, a current ratio of 0.75 and a debt-to-equity ratio of 2.20. The stock has a market capitalization of $34.74 billion, a PE ratio of 25.79, a price-to-earnings-growth ratio of 1.78 and a beta of 1.20. The firm’s 50 day moving average price is $181.62 and its 200 day moving average price is $188.78. IQVIA has a 12 month low of $154.50 and a 12 month high of $247.04.

IQVIA (NYSE:IQV) last released its quarterly earnings data on Tuesday, May 5th. The medical research company reported $2.90 EPS for the quarter, beating the consensus estimate of $2.83 by $0.07. IQVIA had a net margin of 8.33% and a return on equity of 30.50%. The business had revenue of $4.15 billion during the quarter, compared to the consensus estimate of $4.10 billion. During the same quarter in the prior year, the firm earned $2.70 EPS. The business’s revenue was up 8.4% on a year-over-year basis. IQVIA has set its FY 2026 guidance at 12.650-12.950 EPS. As a group, equities analysts predict that IQVIA will post 11.6 earnings per share for the current year.

IQVIA announced that its board has authorized a stock repurchase program on Thursday, May 7th that allows the company to buyback $2.00 billion in shares. This buyback authorization allows the medical research company to purchase up to 6.8% of its stock through open market purchases. Stock buyback programs are usually an indication that the company’s management believes its shares are undervalued.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in the stock. Ameliora Wealth Management Ltd. bought a new position in IQVIA in the 4th quarter worth about $25,000. Financial Freedom LLC bought a new position in IQVIA in the first quarter worth approximately $25,000. Ascentis Independent Advisors purchased a new position in IQVIA during the 1st quarter worth $25,000. International Assets Investment Management LLC bought a new stake in IQVIA during the 4th quarter valued at $27,000. Finally, Gilpin Wealth Management LLC purchased a new stake in shares of IQVIA in the 4th quarter worth $27,000. Hedge funds and other institutional investors own 89.62% of the company’s stock.

IQVIA Company Profile

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.